BGLC logo

BIONEXUS GENE LAB CORP

BGLCNASDAQ
🏆 #5240 by market capUS Equity
$1.38▼ $0.01 (−1.08%)
Live
🔔
Track BGLC
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.1%
7d▼ 5.8%
14d▼ 14.6%
30d▲ 7.4%
ytd▼ 65.4%
1y▼ 75.5%
🏦Market Cap
$3M
Small Cap
📈Revenue Growth (YoY)
-67.1%
Declining
📊Gross Margin
12.3%
Thin
💵FCF Margin
30.7%
Strong
⚖️P/S Ratio
1.2x
Cheap
Otter Score
68
Fair

Trading Snapshot

Day Range
$1.37 – $1.40
52-Week Range
$1.07 – $6.10
Volume
$1.65B
Avg Volume
$2.01B
Shares Outstanding
2.4M
Next Earnings
Nov 23, 2026

Fundamentals Snapshot

Annual Revenue
$3M
Last Q Revenue
$806,053
P/E Ratio
—
P/S Ratio
1.2x
EPS (TTM)
$-1.25
Dividend Yield
—
Dilution (1yr)
+3.3%

Why Investors Own BGLC

  • ✓High-growth profile — revenue up +20.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 27% gross margin and 9% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BGLC logo

BIONEXUS GENE LAB CORP

BGLC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$7M▼ −21.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
14.6%▲ +7.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$3M▲ +100.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$2M▼ −23.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.9M▲ +3.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2M▼ −$2M YoY
StockOtter · stockotter.space

About BIONEXUS GENE LAB CORP

BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn. Bhd., specializes in the wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other nations within Southeast Asia. These essential chemicals are utilized in the manufacturing of a wide array of products, including handrails, bench tops, components for the automotive and aerospace industries, cleanroom panels, and various instruments. Additionally, through its other subsidiary, BioNexus Gene Lab Sdn. Bhd., the company is involved in the development and provision of non-invasive liquid biopsy tests, designed for the early detection of biomarkers.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
68/100

Analyst Price Target

ⓘ
Average Target
$1.80
▲ +30.8% Upside
High Target$2.15
Low Target$1.49
Based on 40 analysts

Latest News & Updates

🚀
Barron’s·2h ago

BIONEXUS GENE LAB CORP tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift BGLC price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

BIONEXUS GENE LAB CORP announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.